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OBJECTIVES: The purpose of this work was to determine whether the intraperitoneal administration of
glibenclamide as a KATP channel blocker could have an effect on the antinociceptive effects of antidepressants
with different mechanisms of action.
METHODS: Three antidepressant drugs, amitriptyline as a dual-action, nonselective inhibitor of noradrenaline and a
serotonin reuptake inhibitor, fluvoxamine as a selective serotonin reuptake inhibitor and maprotiline as a selective
noradrenaline reuptake inhibitor, were selected, and the effect of glibenclamide on their antinociceptive activities
was assessed in male Swiss mice (25-30 g) using a formalin test.
DISCUSSION: None of the drugs affected acute nociceptive responses during the first phase. Amitriptyline (5, 10 mg/
kg), maprotiline (10, 20 mg/kg) and fluvoxamine (20 and 30 mg/kg) effectively inhibited pain induction caused by
the second phase of the formalin test. Glibenclamide (5 mg/kg) alone did not alter licking behaviors based on a
comparison with the control group. However, the pretreatment of animals with glibenclamide (10 and 15 mg/kg)
partially reversed the antinociceptive effects of fluvoxamine but not those of maprotiline. In addition, the highest
dose of glibenclamide (15 mg/kg) partially prevented the analgesic effect of amitriptyline.
CONCLUSION: Therefore, it seems that adenosine triphosphate-dependent potassium channels have a major role in
the analgesic activity of amitriptyline and fluvoxamine.
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INTRODUCTION
After an annoyance by a noxious stimulus, peripheral
nociceptor fibers translate sensory information into the
dorsal horn of spinal cord and then through central
ascending fibers to brainstem, thalamus and cerebral cortex
for processing and perception of pain. With potentiation of
descending inhibitory outputs including direct pathways
[via gamma aminobutyric acid (GABA), opioids and
cannabinoids] and indirect pathways (via 5-Hydroxytrip-
tamine, noradrenaline, and acetylcholine) and modulation
of sodium and calcium channels, we can overcome and
relieve pain syndromes.1,2
For many years antidepressants have been shown to
possess analgesic activity in different kinds of pain models
in animals. They are frequently used in chronic pain
conditions including diabetic neuropathy, post-herpetic
neuralgia, headaches, cancer, chronic back pain and
phantom limb pain and their effects are unrelated to their
antidepressant effects because the doses used for analgesic
actions are lower than antidepressant effects.3-6 These drugs
can increase noradrenaline (NA) and/or 5-hydroxytripta-
mine (5-HT) concentration in the extracellular space via
inhibition of reuptake by blocking their transporters.
Antidepressants are classified into different classes, some
of them nonselectively block the reuptake of NA and 5-HT
including tricyclic antidepressants such as amitriptyline,
clomipramine and newer ones such as duloxetine and
milnacipran. Some of them are selective for NA (SNRIs)
such as maprotiline, or selective for 5-HT (SSRIs) such as
fluoxetine, sertraline and fluvoxamine.5-7
However it has been shown that blockade of neurotrans-
mitter reuptake is not the only mechanism involved in and
there are additional central and peripheral mechanisms that
contribute to either their antinociceptive actions or even
adverse effects of these drugs. Inhibition of adenosine reup-
take is one of the peripheral mechanisms in antinociceptive
effects of these drugs.8,9 Other potential mechanisms are
inhibiting the functions of several other receptors including 5-
HT2C, 5-HT3 and nicotinic acetylcholine receptors and affect-
ing ion channels, by blocking the activity of voltage-gated Na+
and Ca2+ channels or opening of K+channels.10-15 It has been
shown that antidepressant drugs can potentiate analgesic
effect of opioids by increasing the level of opioids.16,17
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Modulation of microglia activation is another mechanism
counteracting with excitotoxicity induced by glutamate that
has an important role in pain signaling.18 In a recent study it
has been indicated that amitriptyline increases reuptake of
glutamate through its transporters resulting in prevention of
N-methyl-D-aspartate (NMDA) induced excitotoxicity.19-20
Neural K+ channels are typically classified to four classes
according to their structure, and specific agonists and
antagonists that consist of voltage-gated (Kv), calcium-
activated (KCa), inward rectifier (Kir) and two-pore (K2P) K
+
channels. It has been established that central K+ channels
especially ATP-sensitive K+ channels (KATP) belonging to the
Kir family are involved in the perception of pain.
21 Central
administration of K+channel openers, such as diazoxide,
minoxidil, lemakalim and cromakalim, produced antinoci-
ception and potentiated analgesic effect produced by opioid
and a2-adrenoceptor agonists.
22,23 Furthermore, central
administration of ATP dependent K+channel blocker, gliqui-
done, a sulfonylurea, reversed the analgesic action of
amitriptyline and clomipramine in a hot plate test.15 In
another study intracerebro-ventricular injection of antisense
oligonucleotide produced a dose-dependent inhibition of
clomipramine and amitriptyline antinociception.24 It seems
that activation of G-protein coupled receptors by agonists
such as a2-adrenoceptors, opioids, GABAB, muscarinic M2,
adenosine A1, serotonin 5-HT1A and cannabinoid receptors
and some nonsteroidal anti-inflammatory drugs (NSAIDs)
can activate these K+ channels.21 The purpose of this work
was to examine if intraperitoneal administration of a KATP
blocker, glibenclamide, one of the most important drugs in
treatment of diabetic patients could also affect antinociptive
effects of antidepressants with different mechanisms of
action with respect to reuptake inhibition of 5-HT or NA.
For this purpose, the effect of pretreatment with glibencla-
mide on the analgesic effect of amitriptyline as a dual action,
non selective inhibitor of noradrenaline and serotonin
reuptake, fluvoxamine as a selective serotonin reuptake
inhibitor (SSRI) and maprotiline as a selective noradrenaline
reuptake inhibitor (SNRI) was assessed in mice.
MATHERIAL AND METHODS
Animals
Male NMRI mice (Pasteur Institute, Tehran, Iran), weight
range between 25-30 g were used. They were housed in
cages in groups of six at 21¡ 2 C˚ in a 12 h light-dark cycle.
Tap water and standard food pellets were available ad
libitum. In order to minimize circadian rhythm influence, all
experiments were conducted between 08:00 and 13:00 h, in a
noise-free room with controlled lighting. Minimum of six
mice were used for each treatment group. All procedures
were approved by the Ethical Committee of the Isfahan
University of Medical Sciences, and conducted in accor-
dance with the internationally accepted principles for
laboratory animal use and care. At the end of the experi-
ments animals sacrificed in an ether chamber. Thirty
minutes before testing, animals were placed in observation
plexiglas box for accommodation.
Drugs
The following drugs were used: Amitriptyline hydro-
chloride (Iran Daru Pharmaceutical Co., Tehran, Iran),
maprotiline (Razk Pharmaceutical Co., Tehran, Iran), flu-
voxamine (Abidi Pharmaceutical Co., Tehran, Iran) and
glibenclamide (Sigma, St Louis, Mo, USA). All drugs except
glibenclamide were dissolved in normal saline 0.9% (w/v)
and glibenclamide was suspended in water using 0.05% (w/
v) carboxymethylcellulose. Glibenclamide was injected
15 min before antidepressant drugs and antidepressants
administered 30 min prior to foot pad injection of formalin.
Measurement of antinociceptive activity
For evaluating antinociceptive effect of drugs we used
formalin test in mice. This is a widely used assay for
analgesic agents, which allow explaining the effects of
analgesic agents used in clinical practice and is consumed a
method for clinical inflammatory pain.25 This method
consists of two phase, phase I (acute phase, 0-5 min) and
phase II (tonic phase, 20-40 min). Irritation in phase I
produced by stimulation of nociceptors during the first
5 min after intra-plantar formalin injection and phase II is
due to central sensitization inflammatory pathways. Twenty
micro-liter of diluted formalin (2.5%) was injected sub-
cutaneously into the dorsal surface of the right hind paw.
Animals were then returned to the chambers, and measure-
ment of the time spent for paw licking was performed
during 0-5 (phase I) and 20-40 min (phase II) periods after
formalin injection by a skilled observer blinded to drug
treatments. All drugs were administered via intraperitoneal
injections (i.p.).
Statistical analysis
The data were expressed as mean ¡ SEM and analyzed
by one-way analysis of variance (ANOVA) followed by
Scheffe post-hoc test, using SPSS 15.0 software. P value ,
0.05 was considered significant.
RESULTS
Amitriptyline, fluvoxamine and maprotiline did not
produce any considerable antinociception in the first phase
of formalin test (data not showed). As shown in fig. 1
amitriptyline at doses of 5, 10 mg/kg significantly (P,0.001)
inhibited paw licking behavior of second phase of formalin
test and glibenclamide (15 mg/kg) partially reversed this
effect. Antinociceptive effect of fluvoxamine on phase 2 has
been shown in fig. 2. This drug showed significant analgesia
in phase two, so that the percentage inhibition of paw
licking behavior at doses of 20 and 30 mg/kg were 97% and
99% respectively. Glibenclamide alone had not any effect on
formalin induced pain response, but at doses of 10 mg/kg
and 15 mg/kg could partially reserve analgesic effect of
20 mg/kg fluvoxamine. Fig. 3 shows the effect of maproti-
line on chronic phase of formalin. Maprotiline produced a
considerable analgesic effect in phase two of formalin test at
doses of 10 and 20 mg/kg. However, glibenclamide could
not produce any significant inhibition of maprotiline-
induced analgesia.
DISCUSSION
In this work, analgesic effects of three antidepressants
belonging to different classes was examined in formalin test
which is one of the most common animal tests for
evaluation of analgesic drugs. In this study none of the
drugs could significantly alter licking induced by formalin
in phase one compared to control group, but all three
antidepressants effectively attenuated pain behavior in
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phase two of formalin test that is in agreement with
previous studies.3,5 As indicated, phase 2 of formalin test
is due to central sensitization of inflammatory pathways.
This kind of sensitization is a key mechanism in inducing
chronic pain.26 These data support the beneficial effect of
antidepressants in chronic pain conditions. Glibenclamide
neither in phase 1 nor in phase 2 could attenuate pain
behavior caused by formalin and this is in agreement with
previous studies that showed the sulphonylurea drugs such
as glibenclamide did not cause hyperalgesia or antinocicep-
tion when administered alone.15,22 As it was mentioned in
introduction, activation of G-protein coupled receptors by
agonists such as a2-adrenoceptors, opioids, GABAB, mus-
carinic M2, adenosine A1, serotonin 5-HT1A and cannabinoid
receptors and some nonsteroidal anti-inflammatory drugs
(NSAIDs) can activate K+ channels and this mechanism to
some extent explains their antinociceptive effects.21 In the
absence of analgesic drugs there is no activation of these
Figure 1 - The antinociceptive effect of i.p. administration of amitriptyline and amitriptyline plus glibenclamide on licking behavior
during phase 2 of formalin test. Bars are mean¡ SEM for six animals. * means significantly different from control group (p,0.001) and
# means significantly different from Ami5 group (p,0.05).
Figure 2 - The antinociceptive effect of i.p. administration of fluvoxamine and fluvoxamine plus glibenclamide on licking behavior
during phase 2 of formalin test. Bars are mean¡ SEM for six animals. * means significantly different from control group (p,0.001) and
# means significantly different from Fluv20 group (p,0.05).
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channels and therefore we do not expect K+ channel
blockers alone to exert hyperalgesis or analgesia. As many
other experimental works, our work has some limitations.
One of them is the use of only one dose (5 mg/kg) of
glibenclamide alone for a control group and it would be
better to use doses of 10 and 15 mg/kg of this drug.
In the present study, glibenclamide could diminish
antinociceptive effect produced by amitriptyline a non selec-
tive inhibitor of noradrenaline-serotonin and fluvoxamine
a selective serotonin reuptake inhibitor and it shows that
ATP-dependent K+ channels have some role in antinocicep-
tive activity of these antidepressants. Meanwhile inhibition
of analgesic effect of fluvoxamine was greater than that of
amitriptyline. Glibenclamide even at the highest dose could
not inhibit maprotiline-induced analgesia which shows that
ATP-dependent K+ channels do not mediate its analgesia.
Although Casis et al. showed that maprotiline block delayed
rectifier potassium current in ventricular myocytes, but
further studies are needed to clarify the exact role of these
currents in neuronal pathways affected by maprotiline.27
It has been shown that different mechanisms are
responsible for analgesic effects observed with antidepres-
sants. The main action seems to be an increase in content of
noradrenalin and serotonin in synaptic space followed by
increased activity on their receptors. Serotonin is a
neurotransmitter with complex actions that causes both
inhibition and augmentation of pain perception depending
on the subtype of receptor which is stimulated. Until now
different subtypes of 5-HT receptors have been known,
including 5-HT1 to 5-HT7. Earlier investigations have
indicated that stimulation of 5-HT1A receptor, a Gi-protein-
coupled receptor which is located throughout of central
nervous system (CNS) especially dorsal raphe nucleus
contributes in antinociception by descending pathways.28-
31 Stimulation of this receptor by 5-HT leads to increase in
potassium current and finally decrease in intracellular
cAMP content.28 Robels and coworkers indicated involve-
ment of ATP sensitive potassium channels in analgesic
action of 5-HT1A agonists.
32 With respect to our results and
previous data,15 we can suppose that stimulation of 5-HT1A
receptors by elevated 5-HT in synaptic space by antide-
pressants acting on reuptake of 5-HT, might partially
participate in analgesic activity of these drugs through
affecting on ATP dependent potassium channels. Therefore
opening of these channels have a major role in antinocicep-
tive effects of them. Further work by applying 5HT1A
agonists and antagonists could help to have a better
understanding of these pathways in antinociceptive effect
of antidepressants.
It is also concluded that ATP-sensitive potassium chan-
nels may have no role in antinociceptive effect of maproti-
line as a selective NA reuptake inhibitor because it has not
been affected by a potassium channel blocker glibencla-
mide.
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